Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492370 | 0.90 | ALDH1A1 (0.45) | KDM4EALDH1A1HSD17B10HPGDRAB9A | |
| SCHEMBL1492351 | 0.88 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL1492335 | 0.84 | ALDH1A1 (0.52) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL1492375 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL1492324 | 0.81 | HIF1A (0.38) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL1492249 | 0.81 | SMN1; SMN2 (0.47) | ALDH1A1HPGDMAPK8MAPK9MAPK10 | |
| SCHEMBL10008966 | 0.79 | L3MBTL1 (0.48) | KDM4EALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL10007484 | 0.77 | L3MBTL1 (0.42) | KDM4EALDH1A1HPGDMAPK8MAPK9 | |
| SCHEMBL1492332 | 0.74 | SMN1; SMN2 (0.52) | KDM4EALDH1A1HSD17B10HPGDMAPK10 | |
| SCHEMBL1492261 | 0.73 | TSHR (0.48) | ALDH1A1HPGDMAPTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475660-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | PRKAB1, PRKAG1, PRKAB2 | KDM4E 1540/4885ALDH1A1 1202/4885HSD17B10 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.